Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
Status:
Completed
Trial end date:
2017-02-22
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to investigate the efficacy, safety, and tolerability
of RV 001 (teprotumumab), a fully human anti-IGF1R antibody, administered q3W for 6 months,
in comparison to placebo, in the treatment of participants suffering from active TED.
"Funding Source - FDA OOPD"
Phase:
Phase 2
Details
Lead Sponsor:
Horizon Pharma USA, Inc. River Vision Development Corporation